Livia López-Noriega

Livia López-Noriega

Auto-generated profile, based on publicly available information

Livia López-Noriega

Andalusian Center of Molecular Biology and Regenerative Medicine‐CABIMER Junta de Andalucía‐University of Pablo de Olavide‐University of Seville‐CSIC Seville Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
NCNadia Cobo-Vuilleumier
Nadia Cobo-Vuilleumier
PLPetra I. Lorenzo
Petra I. Lorenzo
NRNoelia García Rodríguez
Noelia García Rodríguez
IGIrene de Gracia Herrera Gómez
Irene de Gracia Herrera Gómez
EFEsther Fuente-Martin
Esther Fuente-Martin
Benoit GauthierBenoit Gauthier
Benoit Gauthier
Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus.

27 October 2015 in Scientific Reports
Verified
Journal Article
Open access
LILorenzo Petra I.
Lorenzo Petra I.
EFEsther Fuente-Martín
Esther Fuente-Martín
Thierry BrunThierry Brun
Thierry Brun
NCNadia Cobo-Vuilleumier
Nadia Cobo-Vuilleumier
CJCarmen María Jimenez-Moreno
Carmen María Jimenez-Moreno
Benoit GauthierBenoit Gauthier
Benoit Gauthier
PAX4 is a key regulator of pancreatic islet development whilst in adult acute overexpression protects β-cells against stress-induced apoptosis and stimulates proliferation. Nonetheless, sustained PAX4 expression promotes β-cell dedifferentiation and hyperglycemia, mimicking β-cell failure in diabetic patients. Herein, we study mechanisms that allow stringent PAX4 regulation endowing favorable β-cell adaptation in response to changing environment without loss of identity. To this end, PAX4 expression was monitored using a mouse bearing the enhanced green fluorescent protein (GFP) and cre recombinase construct under the control of the islet specific pax4 promoter. GFP was detected in 30% of islet cells predominantly composed of PAX4-enriched β-cells that responded to glucose-induced insulin secretion. Lineage tracing demonstrated that all islet cells were derived from PAX4+ progenitor cells but that GFP expression was confined to a subpopulation at birth which declined with age correlating with reduced replication. However, this GFP+ subpopulation expanded during pregnancy, a state of active β-cell replication. Accordingly, enhanced proliferation was exclusively detected in GFP+ cells consistent with cell cycle genes being stimulated in PAX4-overexpressing islets. Under stress conditions, GFP+ cells were more resistant to apoptosis than their GFP- counterparts. Our data suggest PAX4 defines an expandable β-cell sub population within adult islets.

15 February 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JMJose M. Mellado-Gil
Jose M. Mellado-Gil
EFEsther Fuente-Martín
Esther Fuente-Martín
PLPetra I. Lorenzo
Petra I. Lorenzo
NCNadia Cobo-Vuilleumier
Nadia Cobo-Vuilleumier
LLLivia López-Noriega
Livia López-Noriega
Benoit GauthierBenoit Gauthier
Benoit Gauthier
HMG20A (also known as iBRAF) is a chromatin factor involved in neuronal differentiation and maturation. Recently small nucleotide polymorphisms (SNPs) in the HMG20A gene have been linked to type 2 diabetes mellitus (T2DM) yet neither expression nor function of this T2DM candidate gene in islets is known. Herein we demonstrate that HMG20A is expressed in both human and mouse islets and that levels are decreased in islets of T2DM donors as compared to islets from non-diabetic donors. In vitro studies in mouse and human islets demonstrated that glucose transiently increased HMG20A transcript levels, a result also observed in islets of gestating mice. In contrast, HMG20A expression was not altered in islets from diet-induced obese and pre-diabetic mice. The T2DM-associated rs7119 SNP, located in the 3′ UTR of the HMG20A transcript reduced the luciferase activity of a reporter construct in the human beta 1.1E7 cell line. Depletion of Hmg20a in the rat INS-1E cell line resulted in decreased expression levels of its neuronal target gene NeuroD whereas Rest and Pax4 were increased. Chromatin immunoprecipitation confirmed the interaction of HMG20A with the Pax4 gene promoter. Expression levels of Mafa, Glucokinase, and Insulin were also inhibited. Furthermore, glucose-induced insulin secretion was blunted in HMG20A-depleted islets. In summary, our data demonstrate that HMG20A expression in islet is essential for metabolism-insulin secretion coupling via the coordinated regulation of key islet-enriched genes such as NeuroD and Mafa and that depletion induces expression of genes such as Pax4 and Rest implicated in beta cell de-differentiation. More importantly we assign to the T2DM-linked rs7119 SNP the functional consequence of reducing HMG20A expression likely translating to impaired beta cell mature function.

26 January 2016 in Diabetologia
Verified
Journal Article
Open access
PDF file
JMJosé Manuel Mellado-Gil
José Manuel Mellado-Gil
CJCarmen María Jiménez-Moreno
Carmen María Jiménez-Moreno
Alejandro MartinAlejandro Martin
Alejandro Martin
AÁAna Isabel Álvarez-Mercado
Ana Isabel Álvarez-Mercado
EFEsther Fuente-Martin
Esther Fuente-Martin
Benoit GauthierBenoit Gauthier
Benoit Gauthier
Aims/hypothesis A strategy to enhance pancreatic islet functional beta cell mass (BCM) while restraining inflammation, through the manipulation of molecular and cellular targets, would provide a means to counteract the deteriorating glycaemic control associated with diabetes mellitus. The aims of the current study were to investigate the therapeutic potential of such a target, the islet-enriched and diabetes-linked transcription factor paired box 4 (PAX4), to restrain experimental autoimmune diabetes (EAD) in the RIP-B7.1 mouse model background and to characterise putative cellular mechanisms associated with preserved BCM. Methods Two groups of RIP-B7.1 mice were genetically engineered to: (1) conditionally express either PAX4 (BPTL) or its diabetes-linked mutant variant R129W (mutBPTL) using doxycycline (DOX); and (2) constitutively express luciferase in beta cells through the use of RIP. Mice were treated or not with DOX, and EAD was induced by immunisation with a murine preproinsulin II cDNA expression plasmid. The development of hyperglycaemia was monitored for up to 4 weeks following immunisation and alterations in the BCM were assessed weekly by non-invasive in vivo bioluminescence intensity (BLI). In parallel, BCM, islet cell proliferation and apoptosis were evaluated by immunocytochemistry. Alterations in PAX4- and PAX4R129W-mediated islet gene expression were investigated by microarray profiling. PAX4 preservation of endoplasmic reticulum (ER) homeostasis was assessed using thapsigargin, electron microscopy and intracellular calcium measurements. Results PAX4 overexpression blunted EAD, whereas the diabetes-linked mutant variant PAX4R129W did not convey protection. PAX4-expressing islets exhibited reduced insulitis and decreased beta cell apoptosis, correlating with diminished DNA damage and increased islet cell proliferation. Microarray profiling revealed that PAX4 but not PAX4R129W targeted expression of genes implicated in cell cycle and ER homeostasis. Consistent with the latter, islets overexpressing PAX4 were protected against thapsigargin-mediated ER-stress-related apoptosis. Luminal swelling associated with ER stress induced by thapsigargin was rescued in PAX4-overexpressing beta cells, correlating with preserved cytosolic calcium oscillations in response to glucose. In contrast, RNA interference mediated repression of PAX4-sensitised MIN6 cells to thapsigargin cell death. Conclusions/interpretation The coordinated regulation of distinct cellular pathways particularly related to ER homeostasis by PAX4 not achieved by the mutant variant PAX4R129W alleviates beta cell degeneration and protects against diabetes mellitus. The raw data for the RNA microarray described herein are accessible in the Gene Expression Omnibus database under accession number GSE62846.

22 July 2015 in Current Gene Therapy
Verified
Journal Article
Open access
CJCarmen Jimenez-Moreno
Carmen Jimenez-Moreno
IHIrene de Gracia Herrera-Gomez
Irene de Gracia Herrera-Gomez
LLLivia Lopez-Noriega
Livia Lopez-Noriega
LILorenzo Petra I.
Lorenzo Petra I.
NCNadia Cobo-Vuilleumier
Nadia Cobo-Vuilleumier
Alejandro MartinAlejandro Martin
Alejandro Martin
Successful normalization of blood glucose in patients transplanted with pancreatic islets isolated from cadaveric donors established the proof-of-concept that Type 1 Diabetes Mellitus is a curable disease. Nonetheless, major caveats to the widespread use of this cell therapy approach have been the shortage of islets combined with the low viability and functional rates subsequent to transplantation. Gene therapy targeted to enhance survival and performance prior to transplantation could offer a feasible approach to circumvent these issues and sustain a durable functional β-cell mass in vivo. However, efficient and safe delivery of nucleic acids to intact islet remains a challenging task. Here we describe a simple and easy-to-use lentiviral transduction protocol that allows the transduction of approximately 80 % of mouse and human islet cells while preserving islet architecture, metabolic function and glucose-dependent stimulation of insulin secretion. Our protocol will facilitate to fully determine the potential of gene expression modulation of therapeutically promising targets in entire pancreatic islets for xenotransplantation purposes.

20 September 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
LLLivia López‐Noriega
Livia López‐Noriega
NCNadia Cobo‐Vuilleumier
Nadia Cobo‐Vuilleumier
ÁNÁlvaro Jesús Narbona‐Pérez
Álvaro Jesús Narbona‐Pérez
JAJuan Luis Araujo‐Garrido
Juan Luis Araujo‐Garrido
PLPetra Isabel Lorenzo
Petra Isabel Lorenzo
Alejandro MartinAlejandro Martin
Alejandro Martin